TetraLogic slashes IPO price; UK biotech startup spins out of Xention;

@FierceBiotech: Big Biopharmas help fuel $26M round for Sutro's antibody R&D work. News | Follow @FierceBiotech

@JohnCFierce: GEN ranks VCs by total funds under management. Hmmmm. Feature via GEN | Follow @JohnCFierce

@DamianFierce: With fresh hopes and a bunch of new safety data, Orexigen is going back to the FDA with Contrave. Story | Follow @DamianFierce

@EmilyMFierce: 1 in 100 cancers are associated with a particular gene mutation, according to a Sanger Institute study. Story from FierceBiotech Research  | Follow @EmilyMFierce

> TetraLogic Pharmaceuticals is slashing its share price in order to complete an IPO. The biotech now plans to sell 6.5 million shares at $7, down from a range of $13 to $15 a share. The company has now set its sights on a raise of $46 million. Story

> A U.K. biotech startup which was spun out of Xention has taken root in Cambridge, England, raising a little more than $3 million (£1.9 million) to start a mid-stage study of a new cough medicine for COPD patients. The biotech has an impressive scientific pedigree, with Professor Maria Belvisi and Mark Birrell from the National Heart and Lung Institute at Imperial College London and Professor Dave Singh and Jacky Smith from the University of Manchester and University Hospital of South Manchester on the SAB. New Science Ventures, Forbion Capital Partners and Seroba Kernel Life Sciences put up the cash. Release

Medical Device News

@FierceMedDev: Echo Therapeutics finds a China partner for its glucose monitor, satisfies an angry investor. Article | Follow @FierceMedDev

@MarkHFierce: Presenting, our latest issue of FierceDiagnostics--check it out, and tell a friend. Issue | Follow @MarkHFierce

@MichaelGFierce: Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Imploding microbubbles give transdermal patch an edge over arthritis. Story | Follow @GalenMoore

> Ireland resists tougher EU device regulations. More

> LabCorp predicts another 'difficult' year in 2014 as revenues lag. Article

> After losing a $27M judgment to St. Jude Medical, AccessClosure touts a win. News

Pharma News

@FiercePharma: Tuesday's best-read new news: Teva braces for $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: The here and now of track and trace. Editor's corner | Follow @EricPFierce

@CarlyHFierce: Tuesday's most popular special report: Top 10 generics makers by 2012 revenue. Report | Follow @CarlyHFierce

> GlaxoSmithKline pledges $330M to ramp up Relvar production, expand in U.K. Story

> Vice president clears way for FDA to add inspectors in China. Article

> Pricey hep C drugs, beware: Express Scripts plans a showdown. More

Diagnostics News

> French company unveils prenatal test based on licensed Sequenom tech. Story

> DioGenix's venture round fuels expanded trial for MS molecular Dx test. Report

> New Hologic CEO pledges to grow, and not sell, the women's health Dx company. More

> Foundation Medicine shows test's worth as a highly specific blood cancer screening tool. Article

> Invitae's $40M Series E adds rocket fuel to genetic test expansion plans. News

> Sequenta expands reach of ultrasensitive cancer Dx test. Item

Biomarkers News

> Biomarker points to aggressive breast cancer in black women. Story

> Cellular switch biomarker predicts prostate cancer's spread. Piece

> In China, lung cancer biomarker testing is on the rise. More

> Gene biomarker may determine whether some depression drugs will work. News

> New tech promises to speed up biomarker validation. Article

> Inflammatory marker presents a new target for obesity drug developers. Item

Drug Delivery News

> Alliqua CEO: Celgene deal vaults us to 'another level of respectability'. Article

> Protein 'crossing guard' carries Alzheimer's drug past the blood-brain barrier. More

> Imploding microbubbles give transdermal patch an edge for arthritis drugs. News

> Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. Report

> Rutgers team delivers RNA to weaken drug-resistant ovarian cancer. Story

> Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment. Item

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.